Shandong Loncom Pharmaceutical Co., Ltd. possesses extensive experience in the development of active pharmaceutical ingredients (APIs) for anti-cancer APIs. With strong research and development capabilities, the company currently offers more than ten different anti-cancer medications. Loncom Pharma's Anti-cancer APIs signify a robust arsenal in the fight against cancer. These APIs are critical in the development of oncology drugs that inhibit tumor growth and proliferation by targeting specific pathways and receptors associated with cancer. We have Sorafenib Tosylate, Abemaciclib, Relugolix, Darolutamide, Osimertinib Mesylate, Niraparib Tosylate, etc.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
